Recent insights on the medicinal chemistry of metal-based compounds: Hints for the successful drug design

Current Medicinal Chemistry

Volumn 17, Issue 31, 2010, Pages 3739-3750

  Hernandes, M Z ^a   de Pontes, F J S ^a   Coelho, L C D ^a   Moreira, D R M ^a   Pereira, V R A ^b   Leite, A C L ^a  

^a FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Metal complexes; Molecular docking; Organometallics; Protein kinase; Ruthenium; Thiosemicarbazones; Triapine

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; METAL COMPLEX; PROTEIN KINASE;

ACCURACY; ARTICLE; DNA STRUCTURE; DRUG DESIGN; DRUG DNA BINDING; DRUG MECHANISM; DRUG SCREENING; ENZYME INHIBITION; IN VITRO STUDY; INORGANIC CHEMISTRY; MOLECULAR DOCKING; NONHUMAN;

EID: 78449251367     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710793213779     Document Type: Article

References (119)

1. Zhang, C.H.; Lippard, S.J. New metal complexes as potential therapeutics. Curr. Opin. Chem. Biol. 2003, 7, 481-489.
2. Wang, D.; Lippard, S.J. Cellular processing of platinum anticancer drugs. Nat. Rev. Drug Discov. 2004, 4, 307-320.
3. Ang, W.A.; Dyson, P.J. Classical and non-classical ruthenium-based anticancer drugs: towards targeted chemotherapy. Eur. J. Inorg. Chem. 2006, 4003-4018.
4. Che, C.-M.; Siu, F.-M. Metal complexes in medicine with a focus on enzyme inhibition. Curr. Opin. Chem. Biol. 2010, 14, 255-261.
5. Sun, R. W.-Y.; Ma, D.-L.; Wong, E. L.-M.; Che, C.-M. Some uses of transition metal complexes as anti-cancer and anti-HIV agents. Dalton Trans. 2007, 4884-4892.
6. Otero, L.; Vieites, M.; Boianí, L.; Denicola, A.; Rigol, C.; Opazo, L.; Olea-Azar, C.; Maya, J.D.; Morello, A.; Krauth-Siegel, R.L.; Piro, O.E.; Castelano, E.; Cerecetto, H.; Gambino, D.; Gonzalez, M.; Gambino. Novel antitrypanosomal agents based on palladium nitrofurylthiosemicarbazone complexes: DNA and redox metabolism as potential therapeutic targets. J. Med. Chem. 2006, 49, 3322-3331.
7. Newcomb, J.R.; Rivnay, B.; Bastos, C.M.; Ocain, T.D.; Gordon, K.; Gregory, P.; Turci, S.M.; Sterne, K.A.; Jesson, M.; Krieger, J.; Jenson, J.C.; Jones, B. In vitro immunomodulatory activity of ruthenium complexes. Inflamm. Res. 2003, 52, 263-271.
8. Bastos, C.M.; Gordon, K.A.; Ocain, T.D. Synthesis and immunosuppressive activity of ruthenium complexes. Bioorg. Med. Chem. 1998, 8, 147-150.
9. Odisitse, S., Jackson, G.E. In vitro and in vivo studies of N,N - bis[2(2-pyridyl)-methyl]pyridine-2,6-dicarboxamide-copper(II) and rheumatoid arthritis. Polyhedron, 2008, 27, 453-464.
10. Clark, J.E.; Naughton, P.; Shurey, S.; Green, C.J.; Johnson, T.R.; Mann, B.E.; Foresti, R.; Motterlini, R. Cardioprotective actions by a water-soluble carbon monoxide-releasing molecule. Circ. Res. 2003, 93, e2-e8.
11. Rosenberg, B.; Camp, L.V.; Krigas, T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature, 1965, 205, 698-699.
12. Alderden, R.A.; Hall, M.D.; Hambley, T. W. The discovery and development of cisplatin. J. Chem. Educ. 2006, 83, 728-734.
13. Hambley, T.W. The influence of structure on the activity and toxicity of Pt anti-cancer drugs. Coord. Chem. Rev. 1997, 166, 181-223.
14. Ho, Y.-P.; Au-Yeung, S.C.F.; To, K.K.W. Platinum-based anticancer agents: Innovative design strategies and biological perspectives. Med. Res. Rev. 2003, 23, 633-655.
15. Rotondo, E.; Fimiani, V.; Cavallaro, A.; Ainis, T. Does the antitumoral activity of platinum (IV) derivatives result from their in vivo reduction? Tumori 1983, 69, 31-36.
16. Berners-Price, S.J.; Ronconi, L.; Sadler, P.J. Insights into the mechanism of action of platinum anticancer drugs from multinuclear NMR spectroscopy. Prog. Nucl. Magn. Reson. Spectrosc. 2006, 45, 65-98.
17. Sadler, P.J. Protein recognition of platinated DNA. ChemBioChem 2008, 10, 73-74.
18. Ivanov, A.I.; Christodoulou, J.; Parkinson, J.A.; Barnham, K.J.; Tucker, A.; Woodrow, J.; Sadler, P.J. Cisplatin binding sites on human albumin. J. Biol. Chem. 1998, 273, 14721-14730.
19. Guo, Y.; Smith, K.; Petris, M.J. Cisplatin stabilizes a multimeric complex of the human Ctr1 copper transporter. J. Biol. Chem. 2004, 279, 46393-46399.
20. Gianferrara, T.; Bratsos, I.; Alessio, E. A categorization of metal anticancer compounds based on their mode of action. Dalton Trans. 2009, 7588-7598.
21. Huang, R.; Wallqvist, A.; Covell D.G. Anticancer metal compounds in NCI's tumor-screening database: putative mode of action. Biochem. Pharmacol. 2005, 69, 1009-1039.
22. Casini, A.; Gabbiani, C.; Sorrentino, F.; Rigobello, M.P.; Bindoli, A.; Geldbach, T.J.; Marrone, A.; Re, N.; Hartinger, C.J.; Dyson, P.J.; Messori, L. Emerging protein targets for anticancer metallodrugs: inhibition of thioredoxin reductase and cathepsin B by antitumor ruthenium(II)-arene compounds. J. Med. Chem. 2008, 51, 6773-6781.
23. Vergara, E.; Casini, A.; Sorrentino, F.; Zava, O.; Cerrada, E.; Rigobello, M.P.; Bindoli, A.; Laguna, M.; Dyson, P.J. Anticancer therapeutics that target selenoenzymes: synthesis, characterization, in vitro cytotoxicity, and thioredoxin reductase inhibition of a series of gold(I) complexes containing hydrophilic phosphine ligands. ChemMedChem, 2010, 5, 96-102.
24. Mosi, R.; Baird, I.R.; Cox, J.; Anastassov, V.; Cameron, B.; Skerlj, R.T.; Fricker, S.P. Rhenium inhibitors of cathepsin B (ReO(SYS)X (Where Y) S, py; X) Cl, Br, SPhOMe-p)): synthesis and mechanism of inhibition. J. Med. Chem. 2006, 49, 5262-5272.
25. Mura, P.; Camalli, M.; Casini, A.; Gabbiani, C.; Messori, L. Transcis-cis-[RuCl2(DMSO)2(2-amino-5-methyl-thiazole)2], (PMRu52), a novel ruthenium(II) compound acting as a strong inhibitor of cathepsin B. J. Inorg. Biochem. 2010, 104, 111-117.
26. Yu, Y., Kalinowski, D.S., Kovacevic, Z., Siafakas, A.R., Jansson, P.J., Stefani, C., Lovejoy, D.B., Sharpe, P.C., Bernhardt, P.V., Richardson, D.R. Thiosemicarbazones from the old to new: Iron chelators that are more than just ribonucleotide reductase inhibi-tors. J. Med. Chem. 2009, 52, 5271-5294.
27. Lo, Y.-C.; Ko, T.-P.; Su, W.-C.; Su, T.-L.; Wang, A.W.J. Terpyri-dine-platinum(II) complexes are effective inhibitors of mammalian topoisomerases and human thioredoxin reductase 1. J. Inorg. Biochem. 2009, 103, 1082-1092.
28. Chow, K.W.M.; Sun, R.W.Y.; Lam, J.B.B.; Li, C.L.L.; Xu, A.X.; Ma, D.L.; Abagyan, R.; Wang, Y.; Che, C-M. A gold(III) porphyrin complex with antitumor properties targets the Wnt/ -catenin pathway. Cancer Res. 2010, 70, 329-337.
29. Meggers, E. Exploring biologically relevant chemical space with metal complexes. Curr. Opin. Chem. Biol. 2007, 11, 287-292.
30. Schmid, W.F.; John, R.O.; Mühlgassner, G.; Heffeter, P.; Jakupec, M.A.; Galanski, M.; Berger, W.; Arion, V.B.; Keppler, B.K. Metal-based paullones as putative CDK inhibitors for antitumor chemotherapy. J. Med. Chem. 2007, 50, 6343-6355.
31. Xie, P.; Streu, C.; Qin, J.; Bregman, H.; Pagano, N.; Meggers, E.; Marmorstein, R. The crystal structure of BRAF in complex with an organoruthenium inhibitor reveals a mechanism for inhibition of an active form of BRAF kinase. Biochemistry, 2009, 48, 5187-5198.
32. Zhang, X.; Frezza, M.; Milacic, V.; Ronconi, L.; Fan, Y.; Bi, C.; Fregona, D.; Dou, Q.P. Inhibition of tumor proteasome activity by gold-dithiocarbamato complexes via both redox-dependent and - independent processes. J. Cell Biochem. 2010, 109, 162-172.
33. Dive, D.; Biot, C. Ferrocene conjugates of chloroquine and other antimalarials: the development of ferroquine, a new antimalarial. ChemMedChem, 2008, 3, 383-391.
34. Werner, J.; Geldenhuys, K.E.; Gaasch, M.W.; Allen, D.D.; Van der Schyf, C.J. Optimizing the use of open-source software applications in drug discovery. Drug Discov. Today, 2006, 11, 127-132.
35. Storr, T. Design of targeting ligands in medicinal inorganic chemistry. Chem. Soc. Rev. 2006, 35, 534-544.
36. van Rijt, S.H.; Peacock, A.F.H.; Johnstone, R.D.L.; Parsons, S.; Sadler, P.J. Organometallic osmium(II) arene anticancer complexes containing picolinate derivatives. Inorg. Chem. 2009, 48, 1753-1762.
37. Habtemariam, A.; Melchart, M.; Fernandez, F.; Parsons, S.; Oswald, I.D.H.; Parkin, A.; Fabbiani, F.P.A.; Davidson, J.E.; Daw-son, A.; Aird, R.E.; Jodrell, D.I.; Sadler, P.J. Structure-activity relationships for cytotoxic ruthenium(II) arene complexes containing N,N-, N,O-, and O,O-chelating ligands. J. Med. Chem. 2006, 49, 6858-6868.
38. Beckford, F.A.; Shaloski, Jr. M.; Leblanc, G.; Thessing, J.; Lewis-Alleyne, L.C.; Holder, A.A.; Lic, L.; Seeram, N.P. Microwave syn- thesis of mixed ligand diimine-thiosemicarbazone complexes of ru- thenium(II): biophysical reactivity and cytotoxicity. Dalton Trans. 2009, 10757-10764.
39. Silva, H.; Barra, C.V.; Costa, C.F.; Almeida, M.V.; César, E.T.; Silveira, J.N.; Garnier-Suillerot, A.; Paula, F.C.S.; Pereira-Maia, E.C.; Fontes, A.P.S. Impact of the carbon chain length of novel platinum complexes derived from N-alkyl-propanediamines on their cytotoxic activity and cellular uptake. J. Inorg. Biochem. 2008, 102, 767-777.
40. Barreiro, E.J.; Fraga, C.A.M. New insights for multifactorial dis- ease therapy: the challenge of the symbiotic drugs. Curr. Drug Therapy, 2008, 3, 1-13.
41. Ackley, M.C.; Barry, C.G.; Mounce, A.M.; Farmer, M.C.; Springer, B.E.; Day, C.S.; Wright, M.W.; Berners-Price, S.J.; Hess, S.M.; Bierbach, U. Structure-activity relationships in platinum- acridinylthiourea conjugates: effect of the thiourea nonleaving group on drug stability, nucleobase affinity, and in vitro cytotoxic- ity. J. Biol. Inorg. Chem. 2004, 9, 453-461.
42. Choudhury, J.R.; Guddneppanavar, R.; Saluta, G.; Kucera, G.L.; Bierbach, U. Tuning the DNA conformational perturbations in- duced by cytotoxic platinum-acridine bisintercalators: effect of metal cis/trans isomerism and DNA threading groups. J. Med. Chem. 2008, 51, 3069-3072.
43. Ma, Z.; Rao, L.; Bierbach, U.; Replacement of a thiourea-S with an amidine-NH donor group in a platinum-acridine antitumor com- pound reduces the metal's reactivity with cysteine sulfur. J. Med. Chem. 2009, 52, 3424-3427.
44. Kheradi, A.R.; Saluta, G.; Kucera, G.L.; Day, C.S.; Bierbach, U. Synthesis and biological evaluation of platinum-acridine hybrid agents modified with bipyridine non-leaving groups. Bioorg. Med. Chem. Lett. 2009, 19, 3423-3425.
45. Eiter, L.C.; Hall, N.W.; Day, C.S.; Saluta, G.; Bierbach, U. Gold(I) analogues of a platinum-acridine antitumor agent are only moder- ately cytotoxic but show potent activity against Mycobacterium tuberculosis. J. Med. Chem. 2009, 52, 6519-6522.
46. Donnici, C.L.; Araujo, M.H.; Moreira, D.R.M.; Pereira, V.R.A.; Souza, M.A.; Castro, M.C.A.B.; Leite, A.C.L. Ruthenium com- plexes endowed with potent anti-Trypanosoma cruzi activity: synthesis, biological characterization and structure-activity relation- ships. Bioorg. Med. Chem. 2009, 17, 5038-5043.
47. Tardito, S.; Bussolati, O.; Maffini, M.; Tegoni, M.; Giannetto, M.; Dall'Asta, V.; Franchi-Gazzola, R.; Lanfranchi, M.; Pellinghelli, M.A.; Mucchino, C.; Mori, G.; Marchio, L. Thioamido coordina- tion in a thioxo-1,2,4-triazole copper(II) complex enhances non- apoptotic programmed cell death associated with copper accumula- tion and oxidative stress in human cancer cells. J. Med. Chem. 2007, 50, 1916-1924.
48. Raub, T.J. P-Glycoprotein recognition of substrates and circumven- tion through rational drug design. Mol. Pharm., 2006, 3, 3-25.
49. Vock, C.A.; Ang, W.H.; Scolaro, C.; Phillips, A.D.; Lagopoulos, L.; Juilllerat-Jeanneret, L.; Sava, G.; Scopelliti, R.; Dyson, P.J. Development of ruthenium antitumor drugs that overcome multidrug resistance mechanisms. J. Med. Chem. 2007, 50, 2166-2175.
50. Miller, T.W.; Isenberg, J.S.; Robert, D.D. Molecular regulation of tumor angiogenesis and perfusion via redox signaling. Chem. Rev. 2009, 109, 3099-3124.
51. Vacca, A.; Bruno, M.; Boccarelli, A.; Coluccia, M.; Ribatti, D.; Bergamo, A.; Garbisa, S.; Sartor, L.; Sava, G. Inhibition of endo- thelial cell functions and of angiogenesis by the metastasis inhibitor NAMI-A. Br. J. Cancer 2002, 86, 993-998.
52. Hartinger, C.G.; Zorbas-Seifried, S.; Jakupec, M.A.; Kynast, B.; Zorbas, H.; Keppler, B.K. From bench to bedside - preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A). J. Inorg. Biochem. 2006, 100, 891-904.
53. Sun, R.W.-Y.; Ng, M.F.Y.; Zhang, J.; Chui, S.S.Y.; Shek, L.; Lau, T.H.; Che, C.M. Dual anti-angiogenic and cytotoxic prop- erties of ruthenium(III) complexes containing pyrazolato and/or pyrazole ligands. Dalton Trans. 2009, 10712-10716.
54. Ott, I.; Qian, X.; Xu, Y.; Vlecken, D.H.W.; Marques, I.J.; Kubutat, D.; Will, J.; Sheldrick, W.S.; Jesse, P.; Prokop, P.; Bagowski, C.P. A Gold(I) phosphine complex containing a naphthalimide ligand functions as a TrxR inhibiting antiproliferative agent and angio- genesis inhibitor. J. Med. Chem. 2009, 52, 763-770.
55. Wu, C.-P.; Shukla, S.; Calcagno, A.M.; Hall, M.D.; Gottesman, M.M.; Ambudkar, S.V. Evidence for dual mode of action of a thiosemicarbazone, NSC73306: a potent substrate of the multidrug resistance-linked ABCG2 transporter. Mol. Cancer Ther. 2007, 6, 3287-3296.
56. Kumar, G.D.K.; Chavarria, G.E.; Charlton-Sevcik, A.K.; Arispe, W.M.; MacDonough, M.T.; Strecker, T.E.; Chen, S.; Siim, B.G.; Chaplin, D.J.; Trawick, M.L.; Pinney, K.G. Design, synthesis, and biological evaluation of potent thiosemicarbazone based cathepsin L inhibitors. Bioorg. Med. Chem. Lett. 2010, 20, 1415-1419.
57. Rao, V.A.; Klein, S.R.; Agama, K.K.; Toyoda, E.; Adachi, N.; Pommier, Y.; Shacter, E.B. The iron chelator Dp44mT causes DNA damage and selective inhibition of topoisomerase II in breast cancer cells. Cancer Res. 2009, 69, 948-957.
58. Huang, H.; Chen, Q.; Ku, X.; Meng, L.; Lin, L.; Wang, X.; Zhu, C.; Wang, Y.; Chen, Z.; Li, M.; Jiang, H.; Chen, K.; Ding, J.; Liu, H. A Series of -heterocyclic carboxaldehyde thiosemicarbazones inhibit topoisomerase II catalytic activity. J. Med. Chem. 2010, 53, 3048-3064.
59. Beraldo, H. Gambino, D. The wide pharmacological versatility of semicarbazones, thiosemicarbazones and their metal complexes. Mini-Rev. Med. Chem. 2004, 4, 31-39.
60. Matesanz, A.I.; Souza, P. -N-heterocyclic thiosemicarbazone derivatives as potential antitumor agents: a structure-activity rela- tionships approach. Mini-Rev. Med. Chem. 2009, 9, 1389-1396.
61. Hall, M.D.; Salam, N.K.; Hellawell, J.L.; Fales, H.M.; Kensler, C.B.; Ludwig, J.A.; Szakács, G.; Hibbs, D.E.; Gottesman, M.M. Synthesis, activity, and pharmacophore development for isatin- - thiosemicarbazones with selective activity toward multidrug- resistant cells. J. Med. Chem. 2009, 52, 3191-3204.
62. Mendes, I.C. Soares, M.A.; Santos, R.G. Pinheiro, C. Beraldo, H. Gallium(III) complexes of 2-pyridineformamide thiosemicarba- zones: cytotoxic activity against malignant glioblastoma. Eur. J. Med. Chem. 2009, 44, 1870-1877.
63. Pessoa, C.; Ferreira, P.M.P.; Lotufo, L.V.C.; de Moraes, M.O.; Cavalcanti, S.M.T.; Coelho, L.C.D.; Hernandes, M.Z.; Leite, A.C.L.; De-Simone, C.A.; Costa, V.M.A.; Souza, V.M.O. Discovery of phthalimides as immunomodulatory and antitumor drug prototypes. ChemMedChem, 2010, 4, 523-528.
64. Dunn, L.L.; Rahmanto, Y.S.; Richardson, D.R. Iron uptake and metabolism in the new millennium. Trends Cell Biol. 2007, 17, 93-100.
65. Finch, R.A.; Liu, M.-C.; Grill, S.P.; Rose, W.C.; Loomis, R.; Vasquez, K.M.; Cheng, Y.-C.; Sartorelli, A.C. Triapine (3- aminopyridine-2-carboxaldehyde-thiosemicarbazone): a potent in- hibitor of ribonucleotide reductase activity with broad spectrum an- titumor activity. Biochem. Pharmacol. 2000, 59, 983-991.
66. Yu, Y.; Wong, J.; Lovejoy, D.B.; Kalinowski, D.S.; Richardson, D.R. Chelators at the cancer coalface: desferrioxamine to triapine and beyond. Clin. Cancer Res. 2006, 12, 6876-6883.
67. Karp, J.E.; Giles, F.J.; Gojo, I.; Morris, L.; Greer, J.; Johnson, B.; Thein, M.; Sznol, M.; Low, J. A phase I study of the novel ribonu- cleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nu- cleoside analog fludarabine for patients with refractory acute leu- kemias and aggressive myeloproliferative disorders. Leuk. Res. 2008, 32, 71-77.
68. Ma, B.; Goh, B.C.; Tan, E.H.; Lam, K.C.; Soo, R.; Leong, S.S.; Wang, L.Z.; Mo, F.; Chan, A.T.; Zee, B.; Mok T. A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarba- zone (3-AP, Triapine) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells. Invest. New Drugs 2008, 26, 169-73.
69. Kowol, C.R.; Trondl, R.; Heffeter, P.; Arion, V.B.; Jakupec, M.A.; Roller, A.; Galanski, M.; Berger, W.; Keppler, B.K. Impact of metal coordination on cytotoxicity of 3-aminopyridine-2- carboxaldehyde thiosemicarbazone (Triapine) and novel insights into terminal dimethylation. J. Med. Chem. 2009, 52, 5032-5043.
70. Kowol, C.R.; Trondl, R.; Arion, V.B.; Jakupec, M.A.; Lichtscheidl, I.; Keppler, B.K. Fluorescence properties and cellular distribution of the investigational anticancer drug Triapine (3-aminopyridine-2- carboxaldehyde thiosemicarbazone) and its zinc(II) complex. Dalton Trans. 2010, 39, 704-706.
71. Kalinowski, D.S.; Yu, Y.; Sharpe, P.C.; Islam, M.; Liao, Y.-T.; Lovejoy, D.B.; Kumar, N.; Bernhardt, P.V.; Richardson, D.R. De- sign, synthesis, and characterization of novel iron chelators: Struc- ture-activity relationships of the 2-benzoylpyridine thiosemicarba- zone series and their 3-nitrobenzoyl analogues as potent antitumor agents. J. Med. Chem. 2007, 50, 3716-3729.
72. Bernhardt, P.V.; Wilson, G.J.; Sharpe, P.C.; Kalinowski, D.; Richardson, D.R. Tuning the antiproliferative activity of biologi- cally active iron chelators: characterization of the coordination chemistry and biological efficacy of 2-acetylpyridine and 2- benzoylpyridine hydrazone ligands. J. Biol. Inorg. Chem. 2008, 13, 107-119.
73. Richardson, D.R.; Kalinowski, D.S.; Richardson, V.; Sharpe, P.C.; Lovejoy, D.B.; Islam, M.; Bernhardt, P.V. 2-Acetylpyridine thiosemicarbazones are potent iron chelators and antiproliferative agents: redox activity, iron complexation and characterization of their antitumor activity. J. Med. Chem. 2009, 52, 1459-1470.
74. Bernhardt, P.V.; Sharpe, P.C.; Islam, M.; Lovejoy, D.B.; Kali-nowski, D.; Richardson, D.R. Iron chelators of the dipyridylketone thiosemicarbazone class: precomplexation and transmetalation ef- fects on anticancer activity. J. Med. Chem. 2009, 52, 407-415.
75. Casas, J.S.; Castano, M.V.; Cifuentes, M.C.; Garcia-Monteagudo, J.C.; Sanchez, A.; Sordo, J.; Abram, U. Complexes of dichloro[2- (dimethylaminomethyl)phenyl-C-1, N]gold(III),. [Au(damp-C- 1,N)Cl-2],with formylferrocene thiosemicarbazones: synthesis, structure and cytotoxicity. J. Inorg. Biochem. 2004, 98, 1009-1016.
76. Karki, S.S.; Thota, S.; Darj, S.Y.; Balzarini, J.; Clercq, E.D. Syn-thesis, anticancer, and cytotoxic activities of some mononuclear Ru(II) compounds. Bioorg. Med. Chem. 2007, 15, 6632-6641.
77. Kovala-Demertzi, D.; Yadav, P.N.; Wiecek, J.; Skoulika, S.; Varadinova, T.; Demertzis, M.A. Zinc(II) complexes derived from pyridine-2-carbaldehyde thiosemicarbazone and (1E)-1-pyridin-2- ylethan-1-one thiosemicarbazone. Synthesis, crystal structures and antiproliferative activity of zinc(II) complexes. J. Inorg. Biochem. 2006, 100, 1558-1567.
78. Hambley, T.W.; Battle, A.R.; Deacon, G.B.; Lawrenz, E.T.; Fallon, G.D.; Gatehouse, B.M.; Webster, L.K.; Rainone, S. Modifying the properties of platinum(IV) complexes in order to increase biologi- cal effectiveness. J. Inorg. Biochem. 1999, 77, 3-12.
79. Liu, M.C.; Lin, T.S. Sartorelli, A.C. Synthesis and antitumor evaluation of amino derivatives of pyridine-2-carboxaldehyde thiosemicarbazone. J. Med. Chem. 1992, 35, 3672-3677.
80. Rizzolio, F.; Tuccinardi, T.; Caligiuri, I.; Lucchetti, C.; Giordano, A. CDK inhibitors: from the bench to clinical trials. Curr. Drug Targets 2010, 11, 291-302.
81. Fox, C.J.; Hammerman, P.S.; Cinalli, R.M.; Master, S.R.; Chodosh, L.A.; Thompson, C.B. The serine/threonine kinase Pim-2 is a tran- scriptionally regulated apoptotic inhibitor. Genes Dev. 2003, 17, 1841-1854.
82. Mikkers, H.; Nawijn, M.; Allen, J.; Brouwers, C.; Verhoeven, E.; Jonkers, J.; Berns, A. Mice deficient for all PIM kinases display re- duced body size and impaired responses to hematopoietic growth factors. Mol. Cell Biol. 2004, 24, 6104-6115.
83. Xia, Z.; Knaak, C.; Ma, J.; Beharry, Z. M.; Campbell, M.; Wang, W.; Kraft, A.S.; Smith, C.D. Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases. J. Med. Chem. 2009, 52, 74-86.
84. Anand, R.; Maksimoska, J.; Pagano, N.; Wong, E.Y.; Gimotty, P.A.; Diamond, S.L.; Meggers, E.; Marmorstein, R. Toward the development of a potent and selective organoruthenium mammal- ian sterile 20 kinase inhibitor. J. Med. Chem. 2009, 52, 1602-1611.
85. Meggers, E.; Atilla-Gokcumen, G.E.; Gründler, K.; Frias C.; Prokop, A. Inert ruthenium half-sandwich complexes with antican- cer activity. Dalton Trans 2009, 10882-10888.
86. Pagano, N.; Maksimoska, J.; Bregman, H.; Williams, D.S.; Web-ster, R.D.; Xue, F.; Meggers, E. Ruthenium half-sandwich com- plexes as protein kinase inhibitors: derivatization of the pyridocar- bazole pharmacophore ligand. Org. Biomol. Chem. 2007, 5, 1218-1227.
87. Atilla-Gokcumen, G.E.; Pagano, N.; Streu, C.; Maksimoska, J.; Filippakopoulos, P.; Knapp, S.; Meggers, E. Extremely tight bind- ing of a ruthenium complex to glycogen synthase kinase 3. ChemBioChem. 2008, 9, 2933-2936.
88. Bullock, A.N.; Russo, S.; Amos, A.; Pagano, N.; Bregman, H.; Debreczeni, J.É.; Lee, W.H.; von Delft, F.; Meggers, E.; Knapp, S; Crystal structure of the PIM2 kinase in complex with an or- ganoruthenium inhibitor. Plos One 2009, 4, e1-7.
89. Ewing, T.J.A.; Makino, S.; Skillman, A.G.; Kuntz, I. D. DOCK 4.0: Search strategies for automated molecular docking of flexible molecule databases. J. Comput.-Aided Mol. Des. 2001, 15, 411-428.
90. Verdonk, M.L.; Chessari, G.; Cole, J.C.; Hartshorn, M.J.; Murray, C.W.; Nissink, J.W.M.; Taylor, R.D.; Taylor, R. Modeling water molecules in protein-ligand docking using GOLD. J. Med. Chem. 2005, 48, 6504-6515.
91. Morris, G.M.; Goodsell, D.S.; Halliday, R.S.; Huey, R.; Hart, W.E.; Belew, R.K.; Olson, A.J. Automated docking using a La- marckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 1998, 19, 1639-1662.
92. Seng, H.; Von, S.; Tan, K.; Maah, M. J.; Ng, S.; Rahman, R. N.; Caracelli, I.; Ng, C. Crystal structure, DNA binding studies, nucleolytic property and topoisomerase I inhibition of zinc complex with 1,10-phenanthroline and 3-methyl-picolinic acid. Biometals 2010, 23, 99-118.
93. Seng, H.; Ong, H.A.; Rahman Yamin, B. M.; Tiekink, E.R.T.; Tan, K.W.; Maah, M.J.; Caracelli, I.; Ng. C.H. Factors affecting nu- cleolytic efficiency of some ternary metal complexes with DNA binding and recognition domains. Crystal and molecular structure of Zn(phen)(edda). J. Inorg. Biochem. 2008, 102, 1997-2011.
94. Patra, M.; Gasser, G.; Pinto, A.; Merz, K.; Ott, I.; Bandow, J.E.; Metzler-Nolte, N. Synthesis and biological evaluation of chromium bioorganometallics based on the antibiotic platensimycin lead structure. ChemMedChem 2009, 11, 1930-1938.
95. Wu, Y.; Chen, H.; Yang, P.; Xiong, Z. Racemic D,L-. [Co(phen)2dpq]3+-DNA interactions: Investigation into the basis for minor-groove binding and recognition. J. Inorg. Biochem. 2005, 99, 1126-1134.
96. Arockiasamy, D.L.; Radhika, S.; Parthasarathi, R.; Nair, B.U. Syn-thesis and DNA-binding studies of two ruthenium (II) complexes of an intercalating ligand. Eur. J. Med. Chem. 2009, 44, 2044-2051.
97. Rajendiran, V.; Murali, M.; Suresh, E.; Palaniandavar, M.; Peri-asamy, V. S.; Akbarsha, M.A. Non-covalent DNA binding and cy- totoxicity of certain mixed-ligand ruthenium (II) complexes of 2,2'-dipyridylamine and diimines. Dalton Trans. 2008, 16, 2157-2170.
98. Corral, E.; Hotze, A.C.G.; den Dulk, H.; Leczkowska, A.; Rodger, A.; Hannon, M.J.; Reedijk, J. Ruthenium polypyridyl complexes and their modes of interaction with DNA: Is there a correlation be- tween these interactions and the antitumor activity of the com- pounds? J. Biol. Inorg. Chem. 2009, 14, 439-448.
99. Vaqué, M.; Ardévol, A.; Bladé, C.; Salvadó, J.; Blay, M.; Larrea-Fernández, J.; Arola, L.; Pujadas, G. Protein-ligand docking: a re- view of recent advances and future perspectives. Curr. Pharm. Anal. 2008, 4, 1-19.
100. Nath, B.B.; Babrekar, A.A.; Parthasarathy, B. Assessment of cell viability in intact glandular tissue in chironomus ramosus using dye-exclusion and colorimetric assays. Cytotechnology, 2005, 49, 59-65.
101. Gao, E.; Zhu, M.; Liu, L.; Huang, Y.; Wang, L.; Shi, C.; Zhang, W.; Sun, Y. Impact of the carbon chain length of novel palla- dium(II) complexes on interaction with DNA and cytotoxic activ- ity. Inorg. Chem. 2010, 49, 3261-3270.
102. Burton, J.D. The MTT assay to evaluate chemosensitivity. In Methods in Molecular Medicine, Blumenthal, R.D. (editor), 2005, v. 110.
103. Pechhold, K.; Craighead, N.; Wesh, D.; Kabelitz, D. Measurement of cellular proliferation. Methods Microbiol. 2002, 202, 77-97.
104. Hamid, R.; Rotshteyn, Y.; Rabadi, L.; Parikh, R.; Bullock, P. Com- parison of alamar blue and MTT assays for high through-put scree- ning. Toxicol. In Vitro 2004, 18, 703-710.
105. Immel, T.A.; Debiak, M.; Groth, U.; Brkle, A.; Huhn, T. Highly selective apoptotic cell death induced by halo-salane titanium com- plexes. ChemMedChem 2009, 4, 738-741.
106. Nogueira RC, Costa JFO, Sá MS, Santos RRD, Soares MBP. Early toxicity screening and selection of lead compounds for parasitic diseases. Curr. Drug Targets 2009, 10, 291-298.
107. 2+ and its implications for anticancer drug delivery. J. Inorg. Biochem. 2009, 103, 448-454.
108. Ott, I.; Kircher, B.; Gust, R. Investigations on the effects of cobalt- alkyne complexes on leukemia and lymphoma cells: cytotoxicity and cellular uptake. J. Inorg. Biochem. 2004, 98, 485-489.
109. Michie, J.; Akudugu, J.; Blinder, A.; Van-Resensburg, C.E.J.; Bohn, L. Flow cytometry evaluation of apoptosis and cell viability as a criterion of anti-tumor drug toxicity. Anticancer Res. 2003, 23, 2675-2680.
110. Vermes, I.; Haanen, C.; Reutelingspererger, C. Flow cytometry of apoptotic cell death. J. Immunol. Methods 2000, 243, 167-190.
111. Clarke, M.J.; Zhu, F.; Frasca, D.R. Non-platinum chemotherapeutic metallopharmaceuticals. Chem. Rev. 1999, 99, 2511-2533.
112. Galala, S.A.; Hegab, K.H.; Kassab, A.S.; Rodriguez, M.L.; Kerwin, S.M.; El-Khamry, A.M.A.; El Diwani, H.I. New transition metal ion complexes with benzimidazole-5-carboxylic acid hydrazides with antitumor activity. Eur. J. Med. Chem. 2009, 44, 1500-1508.
113. Wedgwooda, J.L.; Kresinskib, R.A.; Merryc, S.; Platt, A.W.G. The preparation, characterisation and in vitro cytotoxicity of potentially chemotherapeutic heterobimetallic complexes containing early and late transition metals. J. Inorg. Biochem. 2003, 95, 149-156.
114. Tayyem, H.; Huq, F.; Qing-Yu, J.; Beale, P.; Fisher, K. Synthesis and activity of a trinuclear platinum complex:. [{trans-PtCl (NH3)2}2m-{trans-Pt(3- hydroxypyridine)H2N. [(CH2)6NH2)2}] Cl4 in ovarian cancer cell lines. ChemMedChem 2008, 3, 145-151.
115. Kubinyi H. Drug research: myths, hype and reality. Nat. Rev. Drug Discov. 2003, 3, 665-668.
116. Druilhe, P.; Hagan, P.; Rook, G.A.W. The importance of models of infection in the study of disease resistance. Trends Microbiol. 2002, 10, S38-S46.
117. Park, B.K.; Kitteringham, N.R.; Maggs, J.L.; Pirmohamed, M.; Williams, D.P. The role of metabolic activation in drug-induced hepatotoxicity. Ann. Rev. Pharm. Toxicol. 2005, 45, 177-202.
118. Bego, A.M.; Frem, R.C.G.; Netto, A.V.G.; Mauro, A.E.; Ananias, S.R.; Carlos, I.Z.; Rocha, M.C. Immunomodulatory effects of pal- ladium(II) complexes of 1,2,4-triazole on murine peritoneal ma- crophages. J. Braz. Chem. Soc. 2009, 20, 437-444.
119. Sun, R.W.-Y.; Che, C.-M. The anti-cancer properties of gold(III) compounds with dianionic porphyrin and tetradentate ligands. Co- ord. Chem. Rev. 2009, 253, 1682-1691.